Cocrystal Pharma Completes Dosing in Norovirus Drug Trial, Awaits Efficacy Results
Rapid Read

Cocrystal Pharma Completes Dosing in Norovirus Drug Trial, Awaits Efficacy Results

What's Happening? Cocrystal Pharma, Inc. has announced the completion of dosing in its Phase 1b challenge study for CDI-988, an oral antiviral drug candidate designed for norovirus prevention and treatment. The study, conducted at Emory University School of Medicine, involved 32 healthy adults aged
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.